- Home
- UWMC vs URGN Comparison
UWMC vs URGN Comparison
Compare UWMC & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | UWMC | URGN |
|---|---|---|
| Founded | 1986 | 2004 |
| Country | United States | United States |
| Employees | 9100 | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 922.1M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | UWMC | URGN |
|---|---|---|
| Price | $3.92 | $22.57 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 7 |
| Target Price | $6.36 | ★ $29.29 |
| AVG Volume (30 Days) | ★ 13.7M | 619.3K |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | ★ 10.67% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,128,000.00 |
| Revenue This Year | N/A | $127.17 |
| Revenue Next Year | $17.16 | $73.82 |
| P/E Ratio | $82.22 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.38 | $3.42 |
| 52 Week High | $7.14 | $30.00 |
Technical Indicators
Market Signals| Indicator | UWMC | URGN |
|---|---|---|
| Relative Strength Index (RSI) | 52.64 | 65.65 |
| Support Level | $3.79 | $18.55 |
| Resistance Level | $4.01 | $24.32 |
| Average True Range (ATR) | 0.16 | 1.13 |
| MACD | 0.06 | 0.47 |
| Stochastic Oscillator | 80.70 | 97.02 |
Price Performance
Historical ComparisonAbout UWMC UWM Holdings Corporation
UWM Holdings Corp engages in the origination, sale, and servicing of residential mortgage loans in the wholesale channel. The company provides independent mortgage advisors across the states and the district of Columbia.
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.